FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileZevra Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ZVRA
Zevra Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Zevra Therapeutics, Inc. (ZVRA) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisZVRA
ZVRA
Zevra Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ZVRA
  1. Home
  2. Stocks
  3. Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc.

🇺🇸ZVRA•NASDAQ

Zevra Therapeutics, Inc.

🇺🇸ZVRA•NASDAQ
Market cap
$550.42M
Sentiment

Your view on ZVRA

Mkt Cap
$550.42M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Zevra Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Neil F. McFarlane
Headquarters
1180 Celebration Boulevard, Celebration, FL, US
Industry
Biotechnology
Sector
Healthcare
CEO
Neil F. McFarlane
Headquarters
1180 Celebration Boulevard, Celebration, FL, US
Description

Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.

The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.

Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH).

The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial.

In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA.

The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Zevra Therapeutics, Inc. from FRC's valuation model, read against the market price. ZVRA last traded at $9.25, 7.2× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Zevra Therapeutics, Inc.. Starting points for Zevra Therapeutics, Inc.: P/E 7.2, EPS $1.31, beta 0.99 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Zevra Therapeutics, Inc.. Zevra Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Zevra Therapeutics, Inc.. Trailing twelve-month EPS for Zevra Therapeutics, Inc. stands at $1.31. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$24.60

average of 5 firms, last 12 months

 

$24.60

Low $18.00

Median $24.00

High $35.00

 

Analyst Ratings

Buy7 firms, last 12 months
  • Strong Buy0
  • Buy7
  • Hold0
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.19$0.19$1.26$0.89
Low estimate$0.14$0.17$1.24$0.66
High estimate$0.24$0.21$1.29$1.11
No. of analysts3245
Year-ago EPS$0.211$0.601$1.351—
Growth————

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$40.21M$38.98M$153.70M$176.51M
Low estimate$39.36M$36.37M$152.79M$164.54M
High estimate$41.43M$42.52M$154.96M$183.43M
No. of analysts6377
Year-ago revenue$34.13M$36.22M$106.47M—
Growth+17.8%+7.6%+44.4%—
Recent analyst actions15 rating and price-target changes, latest Nov 16, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Zevra Therapeutics, Inc.. Zevra Therapeutics, Inc. has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ZVRA20 companies · 8 funds
Compare ZVRA with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ALKSAlkermes plcDrug Manufacturers - Specialty & Generic$7.8B
  • ANROAlto Neuroscience, Inc.Biotechnology$1.1B
  • GHRSGH Research PLCBiotechnology$1.3B
  • JAZZJazz Pharmaceuticals plcBiotechnology$15.4B
  • MPLTMapLight Therapeutics, Inc.Biotechnology$294M
  • NBIXNeurocrine Biosciences, Inc.Biotechnology$16.7B
  • NMRANeumora Therapeutics, Inc. Common StockBiotechnology$69M
  • PRAXPraxis Precision Medicines, Inc.Biotechnology$8.7B

More Biotechnology companies

  • NTRBNutriband Inc.NASDAQ$71M
  • NTRBWNutriband Inc.NASDAQ$77M
  • NTRRNeutra Corp.OTC$291,790
  • NURPFNeuren Pharmaceuticals LimitedOTC$1.1B
  • NUVBNuvation Bio Inc.NYSE$1.4B
  • NUZ.AXNeurizon Therapeutics LimitedASX
  • NVAXNovavax, Inc.NASDAQ$1.3B
  • NVCTNuvectis Pharma, Inc.NASDAQ$657M
  • NWBONorthwest Biotherapeutics, Inc.OTC$359M
  • NWPHFNewron Pharmaceuticals S.p.A.OTC$240M
  • NXTCNextCure, Inc.NASDAQ$31M
  • NYMXFNymox Pharmaceutical CorporationOTC$5M

ETFs holding Zevra Therapeutics, Inc.

% of the fund

  • IWMiShares Russell 2000 ETF$76.6B in assets0.02%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
  • JSMDJanus Henderson Small/Mid Cap Growth Alpha ETF$1.0B in assets0.72%
  • XPHState Street SPDR S&P Pharmaceuticals ETF$516M in assets1.36%
  • FDLSInspire Fidelis Multi Factor ETF$255M in assets0.83%
  • JSMLJanus Henderson Small Cap Growth Alpha ETF$379M in assets0.66%
  • BFORBarron's 400SM ETF$238M in assets0.20%
  • SFLOVictoryShares Small Cap Free Cash Flow ETF$887M in assets0.19%

Largest holders first, then the funds most concentrated in ZVRA.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Zevra Therapeutics, Inc., and how their positions are changing. At a $550.4M market value, institutional positions materially move Zevra Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Zevra Therapeutics, Inc. executives and directors. Shares of Zevra Therapeutics, Inc. have traded between $6.19 and $13.16 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Zevra Therapeutics, Inc.. Coverage tracks Zevra Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Zevra Therapeutics, Inc.

ZVRA Analysis
Strong
Past1
Growth5
Health5
Profit5
Value5

News

Latest Market News